Reported Sunday, Bristol Myers Squibb's Phase 3 SCOUT-HCM Trial Of Camzyos Meets Primary Endpoint In Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Bristol Myers Squibb's Phase 3 SCOUT-HCM trial of Camzyos has successfully met its primary endpoint, showing a significant reduction in Valsalva left ventricular outflow tract (LVOT) gradient at Week 28 in adolescents with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). The results suggest that Camzyos could become the first targeted pharmacological therapy for this condition in adolescents. Additionally, the safety profile in adolescents was consistent with that observed in adults, with no new safety concerns reported.